Everest Medicines Ltd (1952.HK)
Company Info
Highlights
HK$15.65B
HK$18.18 - HK$69.00
HK$51.58
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
Everest Medicines Ltd (1952.HK) returned 0.21% year-to-date (YTD) and 85.22% over the past 12 months.
1952.HK
0.21%
4.89%
32.92%
85.22%
N/A
N/A
^GSPC (Benchmark)
-3.77%
7.44%
-5.60%
8.37%
14.12%
10.46%
Monthly Returns
The table below presents the monthly returns of 1952.HK, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | -15.89% | 15.56% | 14.42% | -8.03% | -2.03% | 0.21% | |||||||
| 2024 | -24.98% | 54.02% | -2.69% | 4.04% | -9.82% | -11.20% | -0.20% | 5.94% | 31.16% | 16.02% | 8.89% | 40.38% | 130.38% |
| 2023 | 43.84% | -32.00% | -9.18% | -7.90% | -23.49% | 118.75% | -8.61% | -16.78% | 38.12% | 11.20% | -26.44% | 2.20% | 20.25% |
| 2022 | -25.57% | -7.34% | 8.12% | -29.09% | 19.84% | 2.04% | -27.64% | -26.54% | -37.29% | -17.60% | 85.44% | 51.66% | -50.06% |
| 2021 | 24.30% | -4.34% | -8.63% | -6.59% | 9.10% | 3.07% | -23.75% | -18.51% | 2.50% | -8.64% | -21.25% | -1.69% | -48.60% |
| 2020 | -20.34% | 8.80% | 7.38% | -6.94% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
With an overall rank of 87, 1952.HK is among the top 13% of stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Everest Medicines Ltd (1952.HK) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the Everest Medicines Ltd. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Everest Medicines Ltd was 93.89%, occurring on Oct 24, 2022. The portfolio has not yet recovered.
The current Everest Medicines Ltd drawdown is 52.18%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -93.89% | Feb 17, 2021 | 416 | Oct 24, 2022 | — | — | — |
| -24.89% | Oct 14, 2020 | 12 | Oct 30, 2020 | 50 | Jan 12, 2021 | 62 |
| -16.6% | Jan 26, 2021 | 4 | Jan 29, 2021 | 10 | Feb 16, 2021 | 14 |
| -4.31% | Jan 13, 2021 | 1 | Jan 13, 2021 | 1 | Jan 14, 2021 | 2 |
| -3.41% | Jan 18, 2021 | 1 | Jan 18, 2021 | 2 | Jan 20, 2021 | 3 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Everest Medicines Ltd over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Everest Medicines Ltd is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for 1952.HK relative to other companies in the Biotechnology industry. Currently, 1952.HK has a P/S ratio of 22.1. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for 1952.HK in comparison with other companies in the Biotechnology industry. Currently, 1952.HK has a P/B value of 3.5. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |